Browett P - Search Results

1

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.

Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: browett p. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.

2

[No title available]

[No authors listed] [No authors listed] PMID: 36163871

3

Thalidomide metabolites in mice and patients with multiple myeloma.

Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Muller G, Ching LM. Lu J, et al. Among authors: browett p. Clin Cancer Res. 2003 May;9(5):1680-8. Clin Cancer Res. 2003. PMID: 12738721

4

Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.

Chung F, Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Tingle M, Ching LM. Chung F, et al. Among authors: browett p. Clin Cancer Res. 2004 Sep 1;10(17):5949-56. doi: 10.1158/1078-0432.CCR-04-0421. Clin Cancer Res. 2004. PMID: 15355928

5

The skeletal effects of the tyrosine kinase inhibitor nilotinib.

O'Sullivan S, Lin JM, Watson M, Callon K, Tong PC, Naot D, Horne A, Aati O, Porteous F, Gamble G, Cornish J, Browett P, Grey A. O'Sullivan S, et al. Among authors: browett p. Bone. 2011 Aug;49(2):281-9. doi: 10.1016/j.bone.2011.04.014. Epub 2011 Apr 29. Bone. 2011. PMID: 21550432 Clinical Trial.

6

Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.

O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A. O'Sullivan S, et al. Among authors: browett p. J Bone Miner Res. 2007 Nov;22(11):1679-89. doi: 10.1359/jbmr.070719. J Bone Miner Res. 2007. PMID: 17663639 Free article.

7

Successful allogeneic bone marrow transplant for chronic myeloid leukaemia despite previous interferon-induced cardiomyopathy.

Broady R, Hawkins T, Browett P, Palmer S. Broady R, et al. Among authors: browett p. Bone Marrow Transplant. 1998 Apr;21(8):833-4. doi: 10.1038/sj.bmt.1701188. Bone Marrow Transplant. 1998. PMID: 9603410

8

Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.

Simpson DR, Browett PJ, Doak PB, Palmer SJ. Simpson DR, et al. Among authors: browett pj. Bone Marrow Transplant. 1994 Oct;14(4):635-6. Bone Marrow Transplant. 1994. PMID: 7858540

9

Transformation of essential thrombocythaemia to T cell acute lymphoblastic leukaemia.

Berkahn LC, Nelson J, Ockelford PA, Browett PJ. Berkahn LC, et al. Among authors: browett pj. Leuk Lymphoma. 1996 Jan;20(3-4):347-9. doi: 10.3109/10428199609051630. Leuk Lymphoma. 1996. PMID: 8624479

10

CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.

Burns KE, Goldthorpe MA, Porteus F, Browett P, Helsby NA. Burns KE, et al. Among authors: browett p. Cancer Chemother Pharmacol. 2014 Mar;73(3):651-5. doi: 10.1007/s00280-014-2409-9. Epub 2014 Feb 12. Cancer Chemother Pharmacol. 2014. PMID: 24519754

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters